HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jacques Cantin Selected Research

myelopoietin

10/2002Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jacques Cantin Research Topics

Disease

3Breast Neoplasms (Breast Cancer)
10/2011 - 07/2002
1Neoplasms (Cancer)
10/2011
1Febrile Neutropenia
10/2002
1Neutropenia
10/2002

Drug/Important Bio-Agent (IBA)

1Octreotide (Sandostatin)FDA LinkGeneric
10/2011
1Insulin-Like PeptidesIBA
10/2011
1Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
10/2011
1TamoxifenFDA LinkGeneric
10/2011
1Insulin (Novolin)FDA Link
10/2011
1C-PeptideIBA
10/2011
1Insulin-Like Growth Factor I (IGF-1)IBA
10/2011
1myelopoietinIBA
10/2002
1Filgrastim (Neupogen)FDA Link
10/2002
1Docetaxel (Taxotere)FDA Link
10/2002
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2002
1Doxorubicin (Adriamycin)FDA LinkGeneric
10/2002
1Interleukin-3 Receptors (Interleukin 3 Receptor)IBA
10/2002
1leridistimIBA
10/2002
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
10/2002

Therapy/Procedure

2Therapeutics
10/2011 - 10/2002
1Drug Therapy (Chemotherapy)
10/2002
1Mastectomy (Mammectomy)
07/2002
1Segmental Mastectomy (Lumpectomy)
07/2002